PMID- 34963337
OWN - NLM
STAT- MEDLINE
DCOM- 20220628
LR  - 20220716
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 56
IP  - 8
DP  - 2022 Aug
TI  - Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With 
      Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and 
      Meta-Analysis of Randomized Clinical Trials.
PG  - 898-909
LID - 10.1177/10600280211058385 [doi]
AB  - BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is an 
      innovative form of taxane that has superior antitumor effects; however, the 
      safety profile between nab-paclitaxel and traditional taxanes remains 
      controversial. OBJECTIVE: To determine the burden of adverse events (AEs) in 
      patients with multiple malignancies receiving nab-paclitaxel compared with that 
      in patients receiving traditional taxanes. METHODS: Randomized clinical trials 
      comparing nab-paclitaxel with traditional taxanes (solvent-based paclitaxel 
      [sb-paclitaxel] or docetaxel) in the treatment of primary solid-organ 
      malignancies were included if AEs were reported as an outcome. Statistical 
      analyses were conducted to calculate the summary odds ratio (OR) of the relevant 
      adverse outcomes related to nab-paclitaxel and traditional taxanes. Prespecified 
      subgroup analyses based on intervention and doses, primary tumor sites, and 
      different ethnic groups were also performed. RESULTS: Twelve clinical trials were 
      included in the meta-analysis. Grade 3/4 anemia, thrombocytopenia, and 
      neurotoxicity were more frequent with nab-paclitaxel than with traditional 
      taxanes. Nab-paclitaxel at 100 or 125 mg/m(2)/w dosage was associated with fewer 
      or similar grade 3/4 specific AEs. Allergy was less common with nab-paclitaxel. 
      The median recovery times of neurotoxicity were 25, 64, and 37 days in patients 
      receiving nab-paclitaxel, sb-paclitaxel, and docetaxel, respectively. Elevated 
      incidences of specific AEs were more common in breast cancer and non-Asian 
      patients than in other malignancies and ethnic groups, respectively. CONCLUSION 
      AND RELEVANCE: Nab-paclitaxel increased the risk of hematologic and 
      non-hematologic AEs in general, but anaphylaxis was less common, and the recovery 
      duration of neurotoxicity was shorter. Weekly administration of nab-paclitaxel at 
      a lower dosage provided better tolerance.
FAU - He, Fei
AU  - He F
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Liu, Jiaxuan
AU  - Liu J
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Shen, Xin
AU  - Shen X
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Wang, Zijing
AU  - Wang Z
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Li, Qiao
AU  - Li Q
AUID- ORCID: 0000-0002-4547-1266
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Li, Guohui
AU  - Li G
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20211228
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (130-nm albumin-bound paclitaxel)
RN  - 0 (Albumin-Bound Paclitaxel)
RN  - 0 (Albumins)
RN  - 0 (Solvents)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Albumin-Bound Paclitaxel/adverse effects
MH  - Albumins/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Breast Neoplasms/drug therapy
MH  - Docetaxel/therapeutic use
MH  - Female
MH  - Humans
MH  - *Nanoparticles/adverse effects
MH  - Paclitaxel/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Solvents/therapeutic use
MH  - Taxoids/therapeutic use
PMC - PMC9237853
OTO - NOTNLM
OT  - adverse events
OT  - meta-analysis
OT  - nab-paclitaxel
OT  - neoplasm
OT  - taxanes
COIS- Declaration of Conflicting Interests: The authors declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2021/12/30 06:00
MHDA- 2022/06/29 06:00
PMCR- 2022/06/28
CRDT- 2021/12/29 05:19
PHST- 2021/12/30 06:00 [pubmed]
PHST- 2022/06/29 06:00 [medline]
PHST- 2021/12/29 05:19 [entrez]
PHST- 2022/06/28 00:00 [pmc-release]
AID - 10.1177_10600280211058385 [pii]
AID - 10.1177/10600280211058385 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2022 Aug;56(8):898-909. doi: 10.1177/10600280211058385. Epub 
      2021 Dec 28.